Article info

Download PDFPDF

P-30 IL-16 blood levels and combined polymorphism of CCL11 and IL-16 are the biomarkers to select oxycodone for cancer pain management
Free

Authors

Citation

Matsuoka H, Fujita Y, Tsurutani J, et al
P-30 IL-16 blood levels and combined polymorphism of CCL11 and IL-16 are the biomarkers to select oxycodone for cancer pain management

Publication history

  • First published September 5, 2024.
Online issue publication 
September 05, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.